Novartis flags 7 new tumor cases in children treated with Zolgensma SMA gene therapy

Novartis disclosed seven previously unreported tumor cases in children treated with Zolgensma, its gene therapy for spinal muscular atrophy. The causal link remains uncertain, but the disclosure adds to existing safety signals for the therapy. This matters for regulatory scrutiny and patient risk assessment in gene therapy.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works